IMMUNOME INC (IMNM) Stock News

USA - Nasdaq - NASDAQ:IMNM - US45257U1088 - Common Stock

18.65 USD

+0.12 (+0.65%)

Last: 11/24/2025, 5:20:02 PM

18.65 USD

0 (0%)

After Hours: 11/24/2025, 5:20:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

IMNM Latest News, Press Relases and Analysis

All

Press Releases

18 days ago - By: Immunome, Inc.

Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update

20 days ago - By: Immunome, Inc.

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

24 days ago - By: Immunome, Inc.

Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference

a month ago - By: Immunome, Inc.

Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance

2 months ago - By: Benzinga

Where Immunome Stands With Analysts

3 months ago - By: Benzinga

Where Immunome Stands With Analysts

2 months ago - By: Immunome, Inc.

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Infinimmune

Infinimmune Announces Research Collaboration with Immunome

3 months ago - By: Stocktwits - Mentions: IWMW VTWG

News Image

Immunome Stock Rises After Craig-Hellum Initiates Coverage With $26 Price Target: Here’s Why The Analyst Sees An ‘Attractive Entry Point’

4 months ago - By: The Motley Fool

Immunome (IMNM) Q2 Revenue Surges 382%

3 months ago - By: Immunome, Inc.

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Immunome, Inc.

Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference

4 months ago - By: Zacks Investment Research - Mentions: DTIL

Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates

4 months ago - By: Zacks Investment Research - Mentions: VYGR

Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates

4 months ago - By: Immunome, Inc.

Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Zacks Investment Research - Mentions: JAZZ

Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates

4 months ago - By: Immunome, Inc.

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Immunome, Inc.

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Immunome, Inc.

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Zacks Investment Research

Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet

6 months ago - By: Immunome, Inc.

Immunome to Present at Upcoming Investor Conferences

7 months ago - By: Zacks Investment Research - Mentions: CDXS

Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates

7 months ago - By: Zacks Investment Research - Mentions: BOLT

Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates

7 months ago - By: Yahoo Finance - Mentions: TEVA JPM ENTA PSTV ...

Why Teva Pharmaceuticals Stock Blasted 6% Higher Today

7 months ago - By: Immunome, Inc.

Immunome Reports First Quarter 2025 Financial Results and Provides Business Update

7 months ago - By: Zacks Investment Research

Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to Trade

7 months ago - By: Immunome, Inc.

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

8 months ago - By: Immunome, Inc.

Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference

8 months ago - By: Immunome, Inc.

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)